Xiaorong Zhao1, Wenzhuo Wang1, Dandan Li1, Qingjuan Li1, Yuxuan Zhang1 and Bo Niu1,2*
1Department of Biochemistry and Molecular Biology, Shanxi Medical University, China 2Department of Biotechnology, Beijing Municipal Key Laboratory of Child Development and Nutriomics, ChinaFulltext PDF
Purpose: Although many experimentally validated evidence and clinical data support the link between SHCBP1 (SHC-Binding and Spindle-Associated 1) and cancer, there is no pan-cancer analysis available. Based on various databases, we analyzed the roles assumed by SHCBP1 in different cancers to provide new targets for cancer therapy. Methods: We used versatile public databases such as TIMER, Interactive Analysis of Gene Expression Profile, 2nd Edition (GEPIA), UALCAN, The Cancer Genome Atlas (TCGA), cBioPortal, Clinical Bioinformatics Assistant, DiseaseMeth, TISIDB, Human Protein Atlas (HPA), STRING and Database for Annotation, Visualization, and Integrated Discovery (DAVID) to analyze SHCBP1 expression, mutation, methylation in tumors, as well as its survival analysis, tumor-immune interactions and functional networks. Results: SHCBP1 was highly expressed in most tumors leading to poor prognosis and the degree of expression was positively correlated with the degree of infiltration by activated memory CD4+ T cells. We observed cancer-associated fibroblast infiltration in Breast Invasive Carcinoma (BRCA), Renal Clear Cell Carcinoma (KIRC) and Thyroid Cancer (THCA). Protein kinase activity and microtubules can influence gene enrichment, while "cell cycle", "oocyte meiosis" and "viral carcinogenesis" are possible pathways of SHCBP1 involvement in tumorigenesis. Conclusion: Altogether, our first pan-cancer analysis of SHCBP1 demonstrated its potential as a biomarker for tumor prognosis diagnosis or as a molecular target for immunotherapy.
SHCBP1; Pan-cancer; Prognosis; Molecular targeted therapy
Zhao X, Wang W, Li D, Li Q, Zhang Y, Niu B. SHCBP1: A Novel Potential Molecular Target for Pan-Cancer Therapy. Neurol Disord Stroke Int. 2022; 4(1): 1026.